– Near term payment to Esperion of
– Amendment also includes transfer of certain manufacturing and supply rights to DSE and expansion of collaboration in
DSE has agreed to pay Esperion
The parties also agreed, as part of the resolution:
- for Esperion to transition to DSE manufacturing and supply responsibilities in
Europe and other territories, resulting in significant cost savings and efficiencies for both companies. - to expand their collaboration in
Europe and other territories, to include the potential development and commercialization of a triple formulation product comprising bempedoic acid, ezetimibe and a statin, which could represent significant long-term value for the collaboration. - for DSE to now lead all regulatory communications with the EMA regarding the pending applications.
“We are pleased that this settlement creates value for Esperion today through cash payments and includes additional terms that will continue creating value for both companies going forward. Importantly, today’s settlement allows Esperion and DSE to focus on the business at hand – delivering life-saving drug therapies to millions with high cholesterol,” said
“This is a positive resolution for patients. We look forward to continuing to apply our combined strengths around the world to bring innovative pharmaceutical products to patients with cardiovascular disease, the greatest cause of death and disability globally,” said
Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in
About
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.
About
Media Contacts:
For Esperion:
Investors:
investorrelations@esperion.com
(406) 539-1762
Media:
corporateteam@esperion.com
(616) 443-8438
For
Investor Relations Contact (
DaiichiSankyoIR@daiichisankyo.co.jp
Dr.
wolfgang.schiessl@daiichi-sankyo.eu
+49 151 1714 7317
swood@webershandwick.com
+1 (212) 445-8310
![](https://ml.globenewswire.com/media/YmU4YTUzMDUtNDdkZS00OGNjLTgzNGUtNzZlYWQ3NDMwZmM1LTEwMTg3MTQ=/tiny/Esperion-Therapeutics-Inc-.png)
2024 GlobeNewswire, Inc., source